New cancer clinical trial: A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer

Published on: April 26, 2018 at 12:00PM
Condition:   Ovarian Cancer
Intervention:   Drug: Fluzoparib
Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
Recruiting
https://ift.tt/2HvnnzZ